Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Feb. 2, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on February 1, 2024 the Company granted inducement awards to purchase up to 127,300 shares of common stock to eight new employees under the Company’s 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee’s continued service relationship with Syndax through the applicable vesting dates.
Related news for (SNDX)
- Today’s Top Performers: MoBot’s Market Review 08/05/25 09:00 AM
- MoBot alert highlights: NASDAQ: MLGO, NASDAQ: SNDX, NASDAQ: LTBR, NASDAQ: INEO, NASDAQ: PDSB (05/22/25 07:00 PM)
- Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
- Syndax Announces Participation at Two Upcoming Investor Conferences